“Uveitis – Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Uveitis – Pipeline Review, H2 2015’, provides an overview of the Uveitis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– The report provides a snapshot of the global therapeutic landscape of Uveitis
– The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in the therapeutics development for Uveitis and enlists all their major and minor projects
– The report summarizes all the dormant and discontinued pipeline projects
– A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– A detailed assessment of monotherapy and combination therapy pipeline projects
– Coverage of the Uveitis pipeline on the basis of target, MoA, route of administration and molecule type
– Latest news and deals relating related to pipeline products
Reasons to buy
– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Develop strategic initiatives by understanding the focus areas of leading companies
– Identify and understand important and diverse types of therapeutics under development for Uveitis
– Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
– Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline”
“Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Uveitis Overview 8
Therapeutics Development 9
Pipeline Products for Uveitis – Overview 9
Pipeline Products for Uveitis – Comparative Analysis 10
Uveitis – Therapeutics under Development by Companies 11
Uveitis – Therapeutics under Investigation by Universities/Institutes 13
Uveitis – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Uveitis – Products under Development by Companies 17
Uveitis – Products under Investigation by Universities/Institutes 21
Uveitis – Companies Involved in Therapeutics Development 22
2-BBB Medicines BV 22
AbbVie Inc. 23
Aciont Inc. 24
Aldeyra Therapeutics, Inc. 25
Apitope International NV 26
Bristol-Myers Squibb Company 27
Can-Fite BioPharma Ltd. 28
Clearside BioMedical, Inc. 29
Effimune SAS 30
Endocyte, Inc. 31
Enzo Biochem, Inc. 32
EyeGate Pharmaceuticals, Inc. 33
HanAll Biopharma Co., Ltd. 34
Icon Bioscience, Inc. 35
IMMD Inc. 36
Innomedica Ltd. 37
Johnson & Johnson 38
Kineta, Inc. 39
Neuroptis Biotech 40
Novartis AG 41
Ocata Therapeutics, Inc. 42
OncoNOx ApS 43
Palatin Technologies, Inc. 44
Panoptes Pharma Ges.m.b.H. 45
Pfizer Inc. 46
pSivida Corp. 47
Regeneron Pharmaceuticals, Inc. 48
Santen Pharmaceutical Co., Ltd. 49
SynDevRx, Inc. 50
ThromboGenics NV 51
TxCell SA 52
Virogenomics, Inc. 53
XOMA Corporation 54
Uveitis – Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Target 56
Assessment by Mechanism of Action 59
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
2B3-201 – Drug Profile 65
abatacept – Drug Profile 67
adalimumab – Drug Profile 70
ATXUV-1 – Drug Profile 73
ATXUV-2 – Drug Profile 74
B27-PD – Drug Profile 75
celecoxib – Drug Profile 77
Col-Treg – Drug Profile 79
cyclosporine SR – Drug Profile 81
Cytectin – Drug Profile 82
dalazatide – Drug Profile 83
dexamethasone acetate – Drug Profile 85
dexamethasone acetate – Drug Profile 87
dexamethasone sodium phosphate – Drug Profile 88
Drug for Chronic Uveitis – Drug Profile 90
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders – Drug Profile 91
EC-1496 – Drug Profile 92
EC-1669 – Drug Profile 93
fluocinolone acetonide SR – Drug Profile 94
FR-104 – Drug Profile 96
gevokizumab – Drug Profile 98
HL-036 – Drug Profile 101
IMD-0354 – Drug Profile 102
INV-17 – Drug Profile 103
LFG-316 – Drug Profile 104
LME-636 – Drug Profile 106
lodamin – Drug Profile 107
methotrexate – Drug Profile 108
NOP-3 – Drug Profile 109
NS-2 – Drug Profile 110
Oligonucleotides to Activate IL-10 for Uveitis – Drug Profile 112
OX-1001 – Drug Profile 113
PA-2612 – Drug Profile 114
Peptides to Modulate TCR for Uveitis – Drug Profile 115
piclidenoson – Drug Profile 116
PL-8177 – Drug Profile 118
plastoquinone decyl triphenylphosphonium bromide – Drug Profile 119
PP-001 – Drug Profile 121
PPL-003 – Drug Profile 122
Recombinant Enzymes for Uveitis – Drug Profile 124
sarilumab – Drug Profile 125
sirolimus – Drug Profile 128
Small Molecules to Inhibit 5-lipoxygenase for Uveitis – Drug Profile 130
Stem Cell Therapy for Autoimmune Diseases – Drug Profile 131
TG-931 – Drug Profile 132
TOP-1288 – Drug Profile 133
triamcinolone acetonide – Drug Profile 134
triamcinolone acetonide – Drug Profile 135
Uveitis – Recent Pipeline Updates 137
Uveitis – Dormant Projects 178
Uveitis – Discontinued Products 181
Uveitis – Product Development Milestones 182
Featured News & Press Releases 182
Appendix 191
Methodology 191
Coverage 191
Secondary Research 191
Primary Research 191
Expert Panel Validation 191
Contact Us 191
Disclaimer 192″
“List of Tables
Number of Products under Development for Uveitis, H2 2015 13
Number of Products under Development for Uveitis – Comparative Analysis, H2 2015 14
Number of Products under Development by Companies, H2 2015 15
Number of Products under Investigation by Universities/Institutes, H2 2015 17
Comparative Analysis by Late Stage Development, H2 2015 18
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Development, H2 2015 20
Products under Development by Companies, H2 2015 21
Products under Development by Companies, H2 2015 (Contd..1) 22
Products under Development by Companies, H2 2015 (Contd..2) 23
Products under Development by Companies, H2 2015 (Contd..3) 24
Products under Investigation by Universities/Institutes, H2 2015 25
Uveitis – Pipeline by 2-BBB Medicines BV, H2 2015 26
Uveitis – Pipeline by AbbVie Inc., H2 2015 27
Uveitis – Pipeline by Aciont Inc., H2 2015 28
Uveitis – Pipeline by Aldeyra Therapeutics, Inc., H2 2015 29
Uveitis – Pipeline by Apitope International NV, H2 2015 30
Uveitis – Pipeline by Bristol-Myers Squibb Company, H2 2015 31
Uveitis – Pipeline by Can-Fite BioPharma Ltd., H2 2015 32
Uveitis – Pipeline by Clearside BioMedical, Inc., H2 2015 33
Uveitis – Pipeline by Effimune SAS, H2 2015 34
Uveitis – Pipeline by Endocyte, Inc., H2 2015 35
Uveitis – Pipeline by Enzo Biochem, Inc., H2 2015 36
Uveitis – Pipeline by EyeGate Pharmaceuticals, Inc., H2 2015 37
Uveitis – Pipeline by HanAll Biopharma Co., Ltd., H2 2015 38
Uveitis – Pipeline by Icon Bioscience, Inc., H2 2015 39
Uveitis – Pipeline by IMMD Inc., H2 2015 40
Uveitis – Pipeline by Innomedica Ltd., H2 2015 41
Uveitis – Pipeline by Johnson & Johnson, H2 2015 42
Uveitis – Pipeline by Kineta, Inc., H2 2015 43
Uveitis – Pipeline by Neuroptis Biotech, H2 2015 44
Uveitis – Pipeline by Novartis AG, H2 2015 45
Uveitis – Pipeline by Ocata Therapeutics, Inc., H2 2015 46
Uveitis – Pipeline by OncoNOx ApS, H2 2015 47
Uveitis – Pipeline by Palatin Technologies, Inc., H2 2015 48
Uveitis – Pipeline by Panoptes Pharma Ges.m.b.H., H2 2015 49
Uveitis – Pipeline by Pfizer Inc., H2 2015 50
Uveitis – Pipeline by pSivida Corp., H2 2015 51
Uveitis – Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 52
Uveitis – Pipeline by Santen Pharmaceutical Co., Ltd., H2 2015 53
Uveitis – Pipeline by SynDevRx, Inc., H2 2015 54
Uveitis – Pipeline by ThromboGenics NV, H2 2015 55
Uveitis – Pipeline by TxCell SA, H2 2015 56
Uveitis – Pipeline by Virogenomics, Inc., H2 2015 57
Uveitis – Pipeline by XOMA Corporation, H2 2015 58
Assessment by Monotherapy Products, H2 2015 59
Number of Products by Stage and Target, H2 2015 61
Number of Products by Stage and Mechanism of Action, H2 2015 64
Number of Products by Stage and Route of Administration, H2 2015 66
Number of Products by Stage and Molecule Type, H2 2015 68
Uveitis Therapeutics – Recent Pipeline Updates, H2 2015 141
Uveitis – Dormant Projects, H2 2015 182
Uveitis – Dormant Projects (Contd..1), H2 2015 183
Uveitis – Dormant Projects (Contd..2), H2 2015 184
Uveitis – Discontinued Products, H2 2015 185″
